HCV Program Progress and Clinical Data The BEM/RZR combination demonstrated impressive efficacy in Phase 2 trials, achieving a 98% sustained virologic response at 12 weeks post-treatment (SVR12) in ...

Atea Pharmaceuticals (AVIR) offers a late-stage, best-in-class HCV cure, with significant upside, currently trading below cash. BEM/RZR combines advantages of current first-line HCV therapies — single ...

Good day, ladies and gentlemen, and welcome to the Abbott HCV Program Update. My name is Caris, and I will be your coordinator for today. [Operator Instructions] As a reminder, this call is being ...

Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — A telemedicine program brought high levels of satisfaction and proved cost effective in patients ...

The study, which was an open multi-cohort Markov model, aimed to analyze the clinical and economic outcomes of the United States HCV population from 2018 on. For patients with non-cirrhotic chronic ...

C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class ...

AbbVie ( ABBV) presented positive data from a phase III study, TURQUOISE-II, on its investigational hepatitis C virus (HCV) regimen at the recently held International Liver Congress. The results from ...

Regulus Therapeutics Inc. is halting development of its lead microRNA candidate, RG-101, an N-acetylgalactosamine (GalNAc)-conjugated asset targeting miR-122 in chronic hepatitis C virus (HCV), rather ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Since its introduction in April 2015, the nation of ...